Please ensure Javascript is enabled for purposes of website accessibility

Is Xenon Pharmaceuticals a Good Stock to Buy Now?

By Cory Renauer – Oct 5, 2021 at 5:42AM

Key Points

  • Xenon Pharmaceuticals stock recently shot up in response to clinical-trial results for an experimental new epilepsy drug called XEN1101.
  • XEN1101 is similar to an epilepsy drug from the FDA approved nearly a decade ago, with a much-improved safety profile.
  • At recent prices, it doesn't look like the stock market appreciates XEN1101's potential for success as a new epilepsy drug.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.

Shares of Xenon Pharmaceuticals (XENE -2.53%), a biopharmaceutical company developing neurology drugs, shot up on Monday. Better-than-expected trial results for a potential new epilepsy treatment that has blockbuster potential written all over it did the trick. 

Buying stocks just because they're going up isn't a great strategy, but you're right to wonder if this one can climb higher. Before diving in, let's see why everyone's talking about this small-cap biotech right now.

Person sitting in front of a computer and looking at documents on the desk.

Image source: Getty Images.

Epilepsy specialist

Xenon Pharmaceuticals' recent stock market performance was driven by clinical trial success for XEN1101. This is an in-house version of XEN496, a Kv7 potassium channel modulator that Xenon Pharmaceuticals licensed from GlaxoSmithKline (GSK -2.37%) in 2018.

GlaxoSmithKline used to market XEN496 as Potiga, but a side effect led the big pharma to pull it from the market. Potiga never had a chance at achieving significant sales as a treatment for the large population of relatively healthy epilepsy patients who experience focal seizures. It had a troubling tendency to change eye color, a condition that led to vision loss for some unfortunate patients.

As a treatment for a more severe form of epilepsy, though, the benefits could far outweigh the risks. Xenon Pharmaceuticals is running a phase 3 trial with GlaxoSmithKline's castoff for the treatment of a small, genetically defined group of epilepsy patients who are likely to respond to Kv7 modulation.

Two scientists reviewing data.

Image source: Getty Images.

Why Xenon Pharmaceuticals stock shot higher

This biotech stock also popped recently because it looks like it doesn't even need XEN496. That's important because Xenon Pharmaceuticals had more-than-enough time to share positive data from an ongoing phase 3 study with its most advanced-stage new-drug candidate.

Treatment with XEN1101 safely reduced monthly seizure frequency for patients with focal epilepsy in a phase 2 trial. The median reduction among patients who received the largest dose tested was 52.8%, compared to 18.2% in the placebo group.

This wasn't an easy crowd to please, either. A majority of the volunteers couldn't control their seizure frequency with six or more previous anti-seizure medications. During the study, most of these patients were also taking at least one anti-seizure medication. 

Investors are particularly encouraged by the complete lack of pigmentary abnormalities reported during the study. This is the vision-related side effect that effectively ended Potiga's run as a treatment for the larger population of focal epilepsy patients. Overall, 2.6% of patients who received the high dose of XEN1101 reported a serious side effect, which was the same as the placebo group. 

Person getting ready to push a key on a computer.

Image source: Getty Images.

A good biotech stock to buy now

With a safety profile clearly differentiated from Potiga, XEN1101 could experience a great deal of demand right out of the gate. About 60% of people with epilepsy experience focal seizures.

Despite running up on Monday morning, shares of Xenon Pharmaceuticals appear relatively inexpensive. Biotech stocks tend to trade at mid-single-digit multiples of annual sales.

The company doesn't have any products to sell yet, but XEN1101 could generate more than $1 billion in annual sales several years from now. With a recent market cap of around $1.2 billion, this biotech stock probably has a lot of room to run.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends GlaxoSmithKline. The Motley Fool has a disclosure policy.

Stocks Mentioned

Xenon Pharmaceuticals Stock Quote
Xenon Pharmaceuticals
$37.03 (-2.53%) $0.96
Gsk Plc Stock Quote
Gsk Plc
$37.02 (-2.37%) $0.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.